3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
1
Classical hematology
1
Conditions
Thrombocytopenia
1
Myelodysplastic Syndromes
1
Leukemia
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
fludarabine phosphate
9
Cyclophosphamide
8
Cyclosporine
7
Busulfan
6
Antilymphocyte Serum
6
fludarabine
5
Melphalan
5
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Rivaroxaban
3
Radiotherapy
3
Methylprednisolone
3
Filgrastim
3
Cord Blood Stem Cell Transplantation
3
thymoglobulin
2
ferric carboxymaltose
2
apixaban
2
Whole-Body Irradiation
2
Therapeutics
2
Methotrexate
2
Heparin, Low-Molecular-Weight
2
Hematologic Tests
2
Genetic Counseling
2
Fondaparinux
2
Enoxaparin
2
Educational Status
2
Drug Therapy
2
Dalteparin
2
Cytarabine
2
sulforaphane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Platelet Transfusion
×
Classical hematology
×
Clear all
NCT01615146
2015-09-02
OPTIMAL
Ottawa Hospital Research Institute
Phase NA
Terminated
9 enrolled